Navigation Links
Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
Date:12/4/2007

Two Separate Clinical Studies Planned for Cancer and Inflammatory Disease

PRINCETON, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of two separate investigational new drug applications (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1342, one for the treatment of chronic lymphocytic leukemia (CLL) and the other for rheumatoid arthritis. MDX-1342 is a fully human antibody that targets CD19, a molecule specifically expressed on normal B-cells and malignant B-cells in diseases such as CLL, acute lymphoblastic leukemia, follicular non-Hodgkins lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma.

The IND for the treatment of CLL is for an open-label, multi-dose, dose-escalation Phase I clinical trial for cancer that is expected to enroll up to 52 patients with relapsed or refractory CLL. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1342.

The IND for the treatment of rheumatoid arthritis is for a randomized, single-dose, dose-escalation, placebo-controlled Phase I clinical trial that is expected to enroll up to 90 patients with rheumatoid arthritis. This trial is designed to evaluate the safety and tolerability profile of MDX-1342 and to determine the dose range for B-cell depletion.

"We are pleased with the advancement of a new product candidate from Medarex's proprietary pipeline into clinical trials," said Howard H. Pien, President and CEO of Medarex. "We look forward to the continued development of MDX-1342, which could provide new treatment options for a number of serious conditions."

About
'/>"/>

SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...S, France, July 24 /- NicOx...p-line results from the 52-week,open label safety ...ion of,the 301 phase 3 study for naproxcinod. The ... efficacy was maintained for the one-year duration... assessment scale. In,addition, the results showed...
(Date:7/23/2008)...3 /- Sound Pharmaceuticals (SPI) has ... the FDA for the clinical,testing of a proprietary...otherapy induced hearing loss or ototoxicity. The ... tested in advanced stage lung cancer,and head and...motherapy.,This marks the second development progr...
(Date:7/23/2008)...s Some Areas of the Body Have Greater Concentratio...3 /PRNewswire-USNewswire/ -- Fat removed,from the ...was found to be,an excellent source of stem cells,...reas of the body, reports a Brazilian-based study ... the official medical journal of the,American Soci...
(Date:7/23/2008)... on IND-Enabling Work with Protein Therapeutics th...ement System, CAMBRIDGE, Mass., July 23 /PRNewswi...t has initiated a corporate growth plan with the,a...utive officer and the,establishment of its headqua...odruff Emlen, M.D., a co-founder of the company wh...
Breaking Medicine Technology:NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Endocare Stock to Commence Trading on NASDAQ 3184 1Endocare Stock to Commence Trading on NASDAQ 3184 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 1Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 2Marriage 26 Family 3A Celebrating Holiday Traditions 3178 1Marriage 26 Family 3A Celebrating Holiday Traditions 3178 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 1QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 3QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 4QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 5
(Date:7/25/2008)...ncial results -, LAVAL, QC, July 25 /PRNewswire-F...) today announced that it will host a conference c...ss its second quarter 2008,financial results. Labo...l,results via news release at approximately 7:00 a...by telephone, dial 416-646-3095 or,1-800-814-4859....
(Date:7/25/2008)...stCall/ -- Thoratec,Corporation (Nasdaq: THOR ) a...ry support therapies to save, support and restore ...t its operating results for the second,quarter and... 31., The company will hold a conference call to ...ties to all interested parties at 1:30 p.m.,Pacif...
(Date:7/25/2008)...unction, increases asthma risk, studies find, ,... clean, fresh-smelling home may actually be bad fo...and air freshening products you use. , Recent r...s or air fresheners that contain a certain volatil...ne (1,4 DCB), can reduce lung function by 4 percen...
(Date:7/25/2008)... Society for Gastrointestinal Endoscopy (ASGE) has... bariatric surgery patient. The rising prevalence ... surgical interventions led to a marked increase i... the U.S., from 13,365 in 1998 to 102,794 in 2003....ive patient and the postoperative patient, and app...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...o epidemiologists has provided new information on ... bacteria in Post menopausal women and the associ...s showed that women infected with four bacteria kn...ore likely to have more severe oral bone loss than...
... ruled that Ontario residents can get cold and all...l grocery and corner stores . The Ontario Superio...harmaceutical regulators and the Ontario College o...elling medications containing ephedrine and pseudo...
...x Planck Institute for Brain Research in Frankfurt...icago have discovered that nocturnal fruit bats (...he retinas of most mammals contain two types of ph...ht vision and colour vision, and the more sensitiv...
...rogramme has been heavily promoted by the UK gover...alth care and deliver long term cost savings . But...e and question whether expert patients consume few...hief medical officer, Sir Liam Donaldson, conclude...
Other Medicine News:Health News:Post Menopausal Women are Prone to Gum Disease 2Health News:Canadian Court Rules Grocery Shops can Sell Cold Medications Containing Pseudoephedrine 2Health News:Research on Fruit Bats 2Health News:Research on Fruit Bats 3
... IOL power calculation software. All A-scans and A...e module with SRK II, SRKT, Holladay Dioptimum and...H 5100e are equipped with corneal compression dete...eadings. The only A-Scan in the world with corneal...
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
Medicine Products: